CTAP acts as a selective μ-opioid receptor antagonist with a multitude of applications including the regulation of aggressive behavior in mammals. Activation of μ-opioid receptors in the central nucleus of the amygdala, is responsible for mechanisms related to the control of sodium appetite and regulation of sodium intake.
